Free Trial

Scancell (SCLP) Competitors

Scancell logo
GBX 10.22 -0.13 (-1.21%)
As of 07/18/2025 11:23 AM Eastern

SCLP vs. PRTC, OXB, HZD, FARN, VRP, ARIX, CIR, BVXP, AVCT, and 4BB

Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), Avacta Group (AVCT), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.

Scancell vs. Its Competitors

PureTech Health (LON:PRTC) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Scancell has a net margin of 0.00% compared to PureTech Health's net margin of -17,620.94%. Scancell's return on equity of 98.74% beat PureTech Health's return on equity.

Company Net Margins Return on Equity Return on Assets
PureTech Health-17,620.94% -21.15% -13.39%
Scancell N/A 98.74%-45.28%

In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company Overall Sentiment
PureTech Health Neutral
Scancell Neutral

79.9% of PureTech Health shares are held by institutional investors. Comparatively, 46.5% of Scancell shares are held by institutional investors. 15.9% of PureTech Health shares are held by insiders. Comparatively, 5.0% of Scancell shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PureTech Health presently has a consensus price target of GBX 455, suggesting a potential upside of 231.63%. Given PureTech Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe PureTech Health is more favorable than Scancell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Scancell
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

PureTech Health has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Scancell has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Scancell has lower revenue, but higher earnings than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PureTech Health£521.32K790.54-£91.86M-£24.38-5.63
ScancellN/AN/A-£6.75M-£0.65-15.68

Summary

PureTech Health beats Scancell on 9 of the 13 factors compared between the two stocks.

Get Scancell News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLP vs. The Competition

MetricScancellBiotechnology IndustryMedical SectorLON Exchange
Market Cap£105.90M£129.53M£5.55B£3.02B
Dividend YieldN/A3.74%3.75%5.02%
P/E Ratio-15.683.5928.01165.88
Price / SalesN/A4,198.65432.81285,131.45
Price / Cash7.8613.1936.1627.97
Price / Book-26.2337.888.124.46
Net Income-£6.75M-£90.99M£3.25B£5.90B
7 Day Performance-0.63%0.74%1.68%3.89%
1 Month Performance1.24%5.26%7.30%10.11%
1 Year Performance-21.35%173.84%32.89%81.16%

Scancell Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLP
Scancell
N/AGBX 10.23
-1.2%
N/A-14.8%£105.90MN/A-15.6851
PRTC
PureTech Health
N/AGBX 135.80
-0.9%
GBX 455
+235.1%
-18.9%£407.92M£521.32K-5.57300
OXB
Oxford Biomedica
0.8303 of 5 stars
GBX 365
+2.2%
GBX 390
+6.8%
+9.5%£388.00M£98.31M-2.71891Analyst Forecast
Gap Up
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
FARN
Faron Pharmaceuticals Oy
N/AGBX 200
-3.6%
N/A+59.6%£268.50MN/A-5.3534
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
BVXP
Bioventix
N/AGBX 2,655
-2.6%
N/A-34.2%£139.02M£13.65M17.1712News Coverage
Gap Down
AVCT
Avacta Group
N/AGBX 34.25
+5.4%
N/A-56.0%£130.12M£26.29M-4.41120High Trading Volume
4BB
4basebio
1.7408 of 5 stars
GBX 995.50
+0.6%
GBX 1,600
+60.7%
-33.3%£127.52M£311K-1,276.28101Gap Up
High Trading Volume

Related Companies and Tools


This page (LON:SCLP) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners